Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I - new risk factors and targets for therapy

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 17, Issue 8, 2007, Pages 565-571

  Walldius, Göran ^a,b   Jungner, Ingmar ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c CALAB Medical Laboratories   (Sweden)

Author keywords

apoA I; apoB; apoB apoA I ratio; Cardiovascular risk; LDL cholesterol; Myocardial infarction; Stroke

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

BLOOD; CARDIOVASCULAR DISEASE; EVIDENCE BASED MEDICINE; HUMAN; PRACTICE GUIDELINE; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SHORT SURVEY;

APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; EVIDENCE-BASED MEDICINE; HUMANS; PRACTICE GUIDELINES; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 34548124618     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2007.02.010     Document Type: Short Survey

References (34)

1. Sniderman A.D., Furberg C.D., Keech A., van Lennep J.E.R., Frohlich J., Jungner I., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361 (2003) 777-780
2. Barter P.J., Ballantyne C.M., Carmena R., Castro Cabezas M., Chapman M.J., Couture P., et al. ApoB versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 259 (2006) 247-258
3. Walldius G., and Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 255 (2004) 188-205
4. Walldius G., and Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J Intern Med 259 (2006) 493-519
5. Sniderman A.D., and Marcovina S.M. Apolipoprotein AI and B. Clin Lab Med 26 4 (2006) 733-750
6. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278 Erratum in: Lancet 2005;366:1358.
7. Sniderman A.D., Scantlebury T., and Cianflone K. Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 135 (2001) 447-459
8. Grundy S.M., Cleeman J.I., Merz C.N.B., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44 (2004) 720-732
9. Marcovina S., and Packard C.J. Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Intern Med 259 (2006) 437-446
10. Marcovina S.M., Albers J.J., Henderson L.O., and Hannon W.H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem 39 (1993) 773-781
11. Marcovina S.M., Albers J.J., Kennedy H., Mei J.V., Henderson L.O., and Hannon W.H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material. Clin Chem 40 (1994) 586-592
12. Stein E.A., Sniderman A., and Laskarzewski P. Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Am J Cardiol 96 Suppl. (2005) 36K-43K [discussion 34K-35K]
13. Pischon T., Girman C.J., Sacks F.M., Rifai N., Stampfer M.J., and Rimm E.B. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112 (2005) 3375-3383
14. Steinmetz J., Tarallo P Fournier B., Caces E., and Siest G. Reference limits of apolipoprotein A-I and apolipoprotein B using an IFCC standardized immunonephelometric method. Eur J Clin Chem Clin Biochem 33 (1995) 337-342
15. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., and Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 (2001) 2026-2033
16. Walldius G., Jungner I., Aastveit A.H., Holme I., Furberg C.D., and Sniderman A.D. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 42 (2004) 1355-1363
17. Walldius G., Aastveit A.H., and Jungner I. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med 259 (2006) 259-266
18. Lamarche B., Moorjani S., Lupien P.J., Cantin B., Bernhard P.-M., Dagenais G.R., et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation 94 (1996) 273-278
19. Moss A.J., Goldstein R.E., Marder V.J., Sparks C.E., Oakes D., Greenberg H., et al. Thrombogenic factors and recurrent coronary events. Circulation 99 (1999) 2517-2522
20. van Lennep J.E., Westerveld H.T., van Lennep H.W., Zwinderman A.H., Erkelens D.W., and van der Wall E.E. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol 20 (2000) 2408-2413
21. Talmud P.J., Hawe E., Miller G.J., and Humphries S.E. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 22 (2002) 1918-1923
22. Simes R.J., Marschner I.C., Hunt D., Colquhoun D., Sullivan D., Stewart R.A.H., et al. Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial. Circulation 105 (2002) 1162-1169
23. Yusuf S., Hawken S., Öunpuu S., Dans T., Avezum A., Lanas F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 937-952
24. Lind L., Vessby B., and Sundström J. The apolipoprotein B/A-I ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arterioscler Thromb Vasc Biol 26 (2006) 406-410
25. Sierra-Johnson J., Somers V.K., Kuniyoshi F.H., Garza C.A., Isley W.L., Gami A.S., et al. Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. Am J Cardiol 98 (2006) 1369-1373
26. Durrington PN, Livingstone S, Charlton-Menys V, Colhoun H, Betteridge DJ, Fuller J, et al. Apolipoproteins as predictors of cardiovascular risk in the Collaborative AtoRvastatin Diabetes Study (CARDS). Abstract. XIV Int Symp on Atherosclerosis, Rome, Italy; June 19, 2006. p. 37.
27. Wallenfeldt K., Bokemark L., Wikstrand J., Hulthe J., and Fagerberg B. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 35 (2004) 2248-2252 Correction, Stroke 2005;36:415
28. Schmidt C., Fagerberg B., Wikstrand J., and Hulthe J. ApoB/apoA-I ratio is related to femoral artery plaques and is predictive for future cardiovascular events in healthy men. Atherosclerosis 189 (2006) 178-185
29. Ballantyne C.M., Andrews T.C., Hsia J.A., Kramer J.H., and Shear C. for the ACCESS Study Group. Correlations of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 88 (2001) 265-269
30. Gotto Jr. A.M., Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weiss S., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101 (2000) 477-484
31. Olsson A, Holme I, Pedersen TR - for The IDEAL Steering Committee and Investigators. Apolipoprotein B/A-I ratio is a better discriminator of risk of coronary heart disease than is LDL/HDL cholesterol ratio in the IDEAL study. Abstract. XIV Int Symposium on Atherosclerosis, Rome, Italy; June 20, 2006. p. 161.
32. Kastelein JJ, Holme I, Barter P, Olsson AG, Cater NB, Gaffney M, et al. Superiority of ApoB/ApoA-I ratio for predicting cardiovascular risk in pooled analyses of the incremental decrease in endpoints through aggressive lipid-lowering (IDEAL) and treating to new targets (TNT) trials. Abstract. AHA; Nov. 15, 2006.
33. Nicholls S.J., Tuzcu E.M., Sipahi I., Grasso A.W., Schoenhagen P., Hu T., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297 (2007) 499-508
34. Chan D.C., and Watts G.F. Apolipoproteins as markers and managers of coronary risk. Review. Q J Med 99 (2006) 277-287